Predict your next investment

Venture Capital
biomedvc.com

See what CB Insights has to offer

Investments

82

Portfolio Exits

19

Funds

4

Partners & Customers

1

About BioMedPartners

BioMedPartners is a European venture capital firm providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. BioMedPartners targets the entire industry with a special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

BioMedPartners Headquarter Location

Elisabethenstr. 23

Zurich, CH-4051,

Switzerland

+41 61 270 3535

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest BioMedPartners News

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

May 3, 2022

May 03, 2022 05:00 AM Eastern Daylight Time MUNICH--( BUSINESS WIRE )-- Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners. The new capital will be used to advance Tubulis’ proprietary pipeline of uniquely assembled antibody drug conjugates (ADCs), towards clinical evaluation as well as introduce programs addressing a range of solid tumor indications. The proceeds will enable the company to deliver the true therapeutic potential of ADCs through further innovation of novel payload classes and identification of new cancer targets. “This funding emphasizes that Tubulis is uniquely positioned to consolidate the findings of the last 20 years in the ADC field and translate this understanding into meaningful therapeutic benefits for patients. We have reached an important inflection point in the development of our platform technologies as well as our pipeline of highly novel protein-drug conjugates and we are now focused on unlocking new avenues in the treatment of solid tumors bringing safe and effective ADCs to patients,” said Dominik Schumacher, PhD, CEO and co-founder of Tubulis. “With this capital in place, we will execute on our growth strategy, including important focus areas for our pipeline and for how we can apply our proprietary technologies, biologic insights and new mechanisms of action to enable the true therapeutic value inherent in targeted therapeutics.” In conjunction with the round, Sofia Ioannidou, PhD, Partner at Andera Partners, Thomas Hanke, PhD, EVP, Head of Academic Partnerships at Evotec as well as Jan Van den Bossche, Partner at Fund+ will join Tubulis’ Board of Directors consisting of Sebastian Pünzeler, PhD, Principal at coparion, Dominik Schumacher, PhD, CEO of Tubulis and Christian Grøndahl, MD, DVM, PhD, MBA, the Chairman of the Board. In addition, Valentin Piëch, PhD, Partner at BioMedPartners will take over the board seat from Michael Wacker, PhD, General Partner at BioMedPartners. Biographies for all board members can be found on the website using the following link . “With its unique toolkit of proprietary technologies and its pipeline of differentiated ADC candidates, Tubulis holds a compelling position in the ADC field,” stated Andera Partners’ Sofia Ioannidou, PhD. “We look forward to supporting this talented team in bringing innovative ADCs to patients and are confident that Tubulis has the potential to become a leader in the next era of ADC drug development.” Tubulis’ capability of creating a pipeline of antibody-drug conjugates is based on a diverse range of targeting molecules, novel payloads and proprietary conjugation technologies. They enable the discovery of truly innovative ADCs that go beyond traditional payload classes and can increase antibody conjugation options via novel chemical groups leading to stable, high drug-to-antibody ratios. Tubulis has developed superior Topoisomerase-I linker-payloads with significantly improved pharmacokinetic properties and unique conjugation chemistry enabling access to a novel payload class that has been chemically challenging for conjugation in the past. The company’s lead tumor-targeting assets build upon this technological breadth and are currently in preclinical development addressing several high unmet medical need indications. Tubulis’ pipeline also includes a program for hematological tumors, which is on the path towards IND-readiness. Tubulis remains focused on pairing novel payloads with disease-specific targets to tackle the five deadliest cancer indications globally. Baker McKenzie (Julia Braun) served as counsel for new Series B investors and CMS (Stefan-Ulrich Müller) for Tubulis. About Tubulis Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its growing pipeline and will continue to collaborate with industry partners to usher in a new ADC era and deliver better outcomes for patients. Visit www.tubulis.com or follow us on LinkedIn and Twitter . About Andera Partners Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally. Its teams manage over €3.2 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsor-less transactions (Andera Acto) and ecological transition (Andera Infra). Based in Paris, with offices in Antwerp and Munich, Andera Partners is wholly owned by its teams, which count nearly 90 professionals, of which 56 are investment professionals. It is structured as a partnership and managed by a board of 10 partners. Responsible and committed, the management company regularly forms partnerships with non-profit sector entities and takes concrete action in the fight against global warming. Andera Partners has been certified carbon neutral since 2018. Andera's 15-person life sciences team brings together extensive experience in the life sciences industry, private equity and venture capital. Active since 2000, the team has raised over €1.1 billion through its BioDiscovery family of funds and is currently investing from its new BioDiscovery 6 fund. Since inception, the BioDiscovery funds have invested in more than 75 European and U.S. biotech and medtech companies. For further information, please visit www.anderapartners.com . About Bayern Kapital Bayern Kapital GmbH based in Landshut was founded on the initiative of the Bavarian government in 1995. It is a wholly-owned subsidiary of the Bavarian LfA Förderbank. As the venture capital organisation of the Land of Bavaria, Bayern Kapital provides equity capital financing for the founders of young innovative technology companies in Bavaria. Presently, Bayern Kapital manages thirteen investment funds with a total volume of around €700m. So far, it has invested roughly €350m in about 300 innovative companies in the fields of technology in various sectors including life science, software & IT, medical technology, materials and new materials, nanotechnology and environmental technology. In this way, more than 8000 long-term jobs in sustainable companies have been created in Bavaria. www.bayernkapital.de About BioMedPartners Based in Basel, Switzerland, BioMedPartners is an independent European venture capital firm that acts as lead- or co-lead investor providing private equity to early- to mid-stage life sciences companies. Since 2002, BioMedPartners has invested in several highly innovative companies of which twenty-five have already either successfully been acquired by leading biopharma companies or have completed an IPO. With more than CHF 350 million in capital raised for Life Sciences exclusively and a strong team of experienced industry experts as well as an extensive scientific and pharma network, BioMedPartners has established itself as one of the leading early-stage human healthcare investors in Europe. For further information please visit: www.biomedvc.com About coparion coparion provides venture capital to accelerate momentum and growth. With a current active fund of EUR 275m coparion has the means to do so. coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the coparion team discerns potentials and opens up new perspectives. coparion only invests with co-investors. The fund invests up to EUR 10m per company, usually in several financing rounds of EUR 1-5m each. Investment focus is on German companies in the start-up and early growth phase. coparion is based in Cologne and Berlin. www.coparion.vc About Evotec SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company’s 15 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn . About Fund+ Fund+ is a Belgian venture capital firm that invests in innovative European Life Sciences companies developing drugs, medical devices and diagnostics, with a strong focus on patient-centric approaches and major unmet medical needs. With over €200M in assets under management, Fund+ has built a strong track record since 2015, investing in 17 portfolio companies with two major exits. The fund is managed by a specialist team of seasoned life sciences professionals with healthcare industry, corporate finance and strategy consulting experience, supporting companies throughout their growth cycle. The company aims to maintain a leading position in the Life Sciences sector, creating sustainable value for its shareholders and a tangible impact on society. For more information, please visit: www.fundplus.be About High-Tech Gründerfonds High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 650 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 4 billion into the HTGF portfolio via more than 1,900 follow-on financing rounds. HTGF has also successfully sold interests in more than 150 companies. Fund Investors in the public-private partnership include the Federal Ministry for Economic Affairs and Climate Action, KfW Capital, the Fraunhofer-Gesellschaft and 32 companies.

BioMedPartners Investments

82 Investments

BioMedPartners has made 82 investments. Their latest investment was in ImmunOs Therapeutics as part of their Series B on June 6, 2022.

CBI Logo

BioMedPartners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/7/2022

Series B

ImmunOs Therapeutics

$74M

No

4

5/3/2022

Series B

Tubulis

$63M

No

2

3/16/2022

Series B

Precirix

$87.92M

No

7

3/10/2022

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

8/25/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/7/2022

5/3/2022

3/16/2022

3/10/2022

8/25/2021

Round

Series B

Series B

Series B

Series A - II

Series B

Company

ImmunOs Therapeutics

Tubulis

Precirix

Subscribe to see more

Subscribe to see more

Amount

$74M

$63M

$87.92M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

2

7

10

10

BioMedPartners Portfolio Exits

19 Portfolio Exits

BioMedPartners has 19 portfolio exits. Their latest portfolio exit was Amplyx Pharmaceuticals on April 28, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/28/2021

Acquired

$99M

8

7/15/2019

Acquired

$99M

13

4/18/2019

IPO

$99M

Public

7

2/11/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/30/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/28/2021

7/15/2019

4/18/2019

2/11/2019

3/30/2017

Exit

Acquired

Acquired

IPO

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

8

13

7

10

10

BioMedPartners Fund History

4 Fund Histories

BioMedPartners has 4 funds, including BioMedInvest III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/1/2018

BioMedInvest III

Multi-Stage Venture Capital

Open

$105.43M

4

1/12/2010

BioMedInvest II LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2006

BioMedCredit AG

Subscribe to see more

Subscribe to see more

$99M

10

4/29/2005

BioMedInvest AG I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/1/2018

1/12/2010

12/31/2006

4/29/2005

Fund

BioMedInvest III

BioMedInvest II LP

BioMedCredit AG

BioMedInvest AG I

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Open

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$105.43M

$99M

$99M

$99M

Sources

4

10

10

10

BioMedPartners Partners & Customers

1 Partners and customers

BioMedPartners has 1 strategic partners and customers. BioMedPartners recently partnered with Activaero on October 10, 2009.

Date

Type

Business Partner

Country

News Snippet

Sources

10/29/2009

Partner

Germany

Activaero: Activaero closes a 10.7 Million Euro Series a Financing The international consortium was led by BioMedPartners AG (advising BioMedInvest LP II) and included VI Partners AG, Abalis Finance AG and Vesalius Biocapital I SICAR S.A.

We are convinced that the strength of the unique technology combined with the experience of the team makes Activaero a very attractive investment and we are glad to be able to support Activaero in its further development and commercialization stages , '' commented Gerhard Ries , General Partner at BioMedPartners .

2

Date

10/29/2009

Type

Partner

Business Partner

Country

Germany

News Snippet

Activaero: Activaero closes a 10.7 Million Euro Series a Financing The international consortium was led by BioMedPartners AG (advising BioMedInvest LP II) and included VI Partners AG, Abalis Finance AG and Vesalius Biocapital I SICAR S.A.

We are convinced that the strength of the unique technology combined with the experience of the team makes Activaero a very attractive investment and we are glad to be able to support Activaero in its further development and commercialization stages , '' commented Gerhard Ries , General Partner at BioMedPartners .

Sources

2

BioMedPartners Team

8 Team Members

BioMedPartners has 8 team members, including current Chief Financial Officer, Stefan Fã¤s.

Name

Work History

Title

Status

Stefan Fã¤s

Chief Financial Officer

Current

Stefan Fas

Chief Financial Officer

Current

Henri B. Meier

Founding Partner

Current

Markus Hosang

General Partner

Current

Thomas Mã¶ller

General Partner

Current

Name

Stefan Fã¤s

Stefan Fas

Henri B. Meier

Markus Hosang

Thomas Mã¶ller

Work History

Title

Chief Financial Officer

Chief Financial Officer

Founding Partner

General Partner

General Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.